Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (836)	10/21/2003 12:51:34 PM
From: keokalani'nui	Read Replies (1) of 1005

GTx eyes Nasdaq debut GTx plans to trade on the Nasdaq under the symbol "GTXI." The lead underwriter is Goldman Sachs. The company rang up a loss of $6.25 million in the first six months of the year, wider than the loss of $5.2 million registered in the year-ago period. It's seeking regulatory approval for Acapodene, a prostate cancer medicine, and Andarine, another cancer drug. The company is headed up by Dr. Mitchell Steiner, CEO and co-founder of the company in 1997. He previously specialized in urology and urologic oncology at the University of Tennessee. The chairman of GTx is J.R. Hyde III, who is also president of Pittco Holdings, a private institutional investment company. Hyde made a "substantial contribution" to Steiner's research in 1996 and helped found the company a year later. Hyde was also chairman and former CEO of AutoZone (AZO: news, chart, profile) and serves on the board of FedEx

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next